Income Statement Abbott Laboratories Swiss Exchange
Stocks
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77.50 CHF | +1.97% |
|
+3.33% | -21.72% |
| 07-06 | Evercore ISI Adjusts Abbott Laboratories Price Target to $112 From $120 | MT |
| 07-02 | Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 43.08B | 43.65B | 40.11B | 41.95B | 44.33B | |||||
Total Revenues | 43.08B | 43.65B | 40.11B | 41.95B | 44.33B | |||||
Cost of Goods Sold, Total | 18.07B | 19.08B | 17.92B | 18.64B | 19.21B | |||||
Gross Profit | 25.01B | 24.57B | 22.19B | 23.31B | 25.12B | |||||
Selling General & Admin Expenses, Total | 11.01B | 10.7B | 10.38B | 11.11B | 11.63B | |||||
R&D Expenses | 2.74B | 2.74B | 2.62B | 2.82B | 2.89B | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 2.05B | 2.01B | 1.97B | 1.88B | 1.68B | |||||
Other Operating Expenses, Total | 15.79B | 15.46B | 14.97B | 15.81B | 16.2B | |||||
Operating Income | 9.22B | 9.11B | 7.22B | 7.5B | 8.92B | |||||
Interest Expense, Total | -533M | -558M | -637M | -559M | -493M | |||||
Interest And Investment Income | 43M | 183M | 385M | 344M | 308M | |||||
Net Interest Expenses | -490M | -375M | -252M | -215M | -185M | |||||
Currency Exchange Gains (Loss) | -1M | -2M | -41M | 27M | 50M | |||||
Other Non Operating Income (Expenses) | 7M | -40M | -22M | -166M | -42M | |||||
EBT, Excl. Unusual Items | 8.73B | 8.7B | 6.9B | 7.14B | 8.74B | |||||
Restructuring Charges | -509M | -234M | -144M | -129M | -274M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | -45M | -39M | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | -14M | -111M | -100M | - | - | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | - | - | 42M | - | - | |||||
EBT, Incl. Unusual Items | 8.21B | 8.31B | 6.66B | 7.01B | 8.47B | |||||
Income Tax Expense | 1.14B | 1.37B | 941M | -6.39B | 1.94B | |||||
Earnings From Continuing Operations | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B | |||||
Net Income - (IS) | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B | |||||
Preferred Dividend and Other Adjustments | 29M | 28M | 22M | 51M | 24M | |||||
Net Income to Common Incl Extra Items | 7.04B | 6.9B | 5.7B | 13.35B | 6.5B | |||||
Net Income to Common Excl. Extra Items | 7.04B | 6.9B | 5.7B | 13.35B | 6.5B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 3.97 | 3.94 | 3.28 | 7.67 | 3.73 | |||||
Basic EPS - Continuing Operations | 3.97 | 3.94 | 3.28 | 7.67 | 3.73 | |||||
Basic Weighted Average Shares Outstanding | 1.78B | 1.75B | 1.74B | 1.74B | 1.74B | |||||
Net EPS - Diluted | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | |||||
Diluted EPS - Continuing Operations | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | |||||
Diluted Weighted Average Shares Outstanding | 1.79B | 1.76B | 1.75B | 1.75B | 1.75B | |||||
Normalized Basic EPS | 3.08 | 3.1 | 2.48 | 2.57 | 3.14 | |||||
Normalized Diluted EPS | 3.05 | 3.08 | 2.47 | 2.55 | 3.12 | |||||
Dividend Per Share | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | |||||
Payout Ratio | 45.28 | 47.73 | 62.14 | 28.62 | 63.09 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 12.76B | 12.38B | 10.46B | 10.71B | 12.03B | |||||
EBITA | 11.26B | 11.13B | 9.19B | 9.37B | 10.6B | |||||
EBIT | 9.22B | 9.11B | 7.22B | 7.5B | 8.92B | |||||
EBITDAR | 13.12B | 12.74B | 10.82B | 11.08B | 12.42B | |||||
Effective Tax Rate - (Ratio) | 13.88 | 16.53 | 14.12 | -91.1 | 22.94 | |||||
Current Domestic Taxes | 859M | 1.31B | 528M | 497M | 387M | |||||
Current Foreign Taxes | 790M | 723M | 874M | 1.08B | 1.11B | |||||
Total Current Taxes | 1.65B | 2.03B | 1.4B | 1.57B | 1.5B | |||||
Deferred Domestic Taxes | -355M | -610M | -382M | -459M | -257M | |||||
Deferred Foreign Taxes | -154M | -49M | -79M | -7.5B | 698M | |||||
Total Deferred Taxes | -509M | -659M | -461M | -7.96B | 441M | |||||
Normalized Net Income | 5.46B | 5.44B | 4.32B | 4.46B | 5.46B | |||||
Interest Capitalized | - | - | - | - | - | |||||
Non-Cash Pension Expense | -277M | -399M | -504M | -556M | -622M | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 2.74B | 2.89B | 2.74B | 2.84B | 2.94B | |||||
Net Rental Expense, Total | 359M | 355M | 356M | 366M | 391M | |||||
Imputed Operating Lease Interest Expense | 78.22M | 85.21M | 107M | 105M | 105M | |||||
Imputed Operating Lease Depreciation | 281M | 270M | 249M | 261M | 286M | |||||
Stock-Based Comp., Other (Total) | 640M | 685M | 644M | 673M | 664M | |||||
Total Stock-Based Compensation | 640M | 685M | 644M | 673M | 664M |
- Stock Market
- Stocks
- ABT Stock
- ABT Stock
- Financials Abbott Laboratories
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















